Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy

  • Adam Feuerstein

By Adam Feuerstein March 4, 2018

Reprints
Killer T cells surround a cancer cell
NIH

Correction: An earlier version of this story incorrectly described Unum’s disclosure of data about patient deaths at the American Society of Hematology meeting in December.

Private biotechs are like Instagram posts. The glossy, successful image they choose to share can hide darker truths.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Medical device companies now need to prove to FDA…
Medical device companies now need to prove to FDA they’re protected against cyberattacks
Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

Comments are closed.

Recommended Stories